Table 2: Prophylactics.

Name of the drug

Mode of action

Current status of Clinical trial

References

Hydroxychloroquine

1. Inhibition of virus fusion caused by elevated endosomal pH.

2. Impairment of terminal glycosylation of ACE2.

1. Controversial results.

2. Removed from clinical trial.

[99]

[100]

Azithromycin

1. Increased endosomal pH inhibits viral fusion.

2. Also an immunomodulator.

1. Moderate efficacy.

2. Controversial results.

[101]

[102]

Arbidol hydrochloride

Inhibits viral entry by inhibition of endocytosis or membrane fusion. It also inhibits viral RNA synthesis.

Not yet approved by FDA.

[103]

[104]